CARDENE SR drug interactions: Difference between revisions

Jump to navigation Jump to search
No edit summary
(Redirected page to Nicardipine#Drug Interactions)
 
Line 1: Line 1:
__NOTOC__
#REDIRECT [[Nicardipine#Drug Interactions]]
{{Nicardipine}}
{{CMG}}; {{AE}}:{{AK}}
 
'''''For patient information about Nicardipine, click [[Nicardipine (patient information)|here]].'''''
 
==Drug Interactions==
 
'''Beta-Blockers:''' In controlled clinical studies, adrenergic beta-receptor blockers have been frequently administered concomitantly with CARDENE. The combination is well tolerated.
 
'''Cimetidine''': [[Cimetidine]] increases CARDENE plasma levels. Patients receiving the two drugs concomitantly should be carefully monitored.
 
'''Digoxin:''' Some calcium blockers may increase the concentration of [[digitalis]] preparations in the blood. CARDENE usually does not alter the plasma levels of [[digoxin]]; however, serum digoxin levels should be evaluated after concomitant therapy with CARDENE is initiated.
 
'''Fentanyl Anesthesia:''' Severe hypotension has been reported during [[fentanyl]] anesthesia with concomitant use of a beta-blocker and a calcium channel blocker. Even though such interactions were not seen during clinical studies with CARDENE, an increased volume of circulating fluids might be required if such an interaction were to occur.
 
'''Cyclosporine:''' Concomitant administration of nicardipine and [[cyclosporine]] results in elevated plasma cyclosporine levels. Plasma concentrations of cyclosporine should therefore be closely monitored, and its dosage reduced accordingly, in patients treated with nicardipine.
 
When therapeutic concentrations of [[furosemide]], [[propranolol]], [[dipyridamole]], [[warfarin]], [[quinidine]] or [[naproxen]] were added to human plasma (in vitro), the plasma protein binding of CARDENE was not altered.<ref> {{cite web | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ce141ca0-d734-11df-8537-0002a5d5c51b | title = CARDENE SR (nicardipine hydrochloride) capsule, extended release [EKR Therapeutics] | accessdate =}}</ref>
 
==References==
{{Reflist|2}}
[[Category:Cardiovascular Drugs]]
[[Category:Drugs]]

Latest revision as of 03:14, 22 July 2014